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Abstract. The major impact produced by the severe acute 
respiratory syndrome coronavirus 2 (SARS-coV-2) focused 
many researchers attention to find treatments that can suppress 
transmission or ameliorate the disease. despite the very fast 
and large flow of scientific data on possible treatment solu-
tions, none have yet demonstrated unequivocal clinical utility 
against coronavirus disease 2019 (COVID‑19). This work 
represents an exhaustive and critical review of all available 
data on potential treatments for cOVId-19, highlighting their 
mechanistic characteristics and the strategy development ratio-
nale. Drug repurposing, also known as drug repositioning, and 
target based methods are the most used strategies to advance 
therapeutic solutions into clinical practice. current in silico, 
in vitro and in vivo evidence regarding proposed treatments 
are summarized providing strong support for future research 
efforts.
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1. Introduction
The severe acute respiratory syndrome coronavirus 2 
(SARS-coV-2), provisionally named as 2019-ncoV and collo-
quially known as the coronavirus, is the pandemic‑causing 
pathogen behind coronavirus disease 2019 (COVID‑19), which 
originated in Wuhan, Hubei Province, china in the 4th quarter 
of 2019 (1). despite the rapid delivery of the SARS-coV-2 
genome by the group originally recognizing this novel viral 
pneumonia and the subsequent production of a number 
of highly specific and sensitive molecular diagnostics for 
SARS‑CoV‑2, progress in fighting this disease is balanced by 
the continued lack of ‘quick win’ treatments that can suppress 
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transmission or ameliorate disease. Of the more than 100 
clinical trials evaluating a cadre of approved, or clinical stage 
antivirals and related compounds, none have yet demonstrated 
unequivocal clinical utility against cOVId-19.
The eventual containment and mitigation of this emerging 
disease will depend on our exponentially increasing knowledge 
around SARS-coV-2 virology, pathology, and cross-species 
transmission. With viral genome organization resolved in 
unprecedented speed, molecular pathogenesis and immuno-
pathology related to protein products, modes of transmission, 
host cell entry mechanism and kinetics, vesicular trafficking, 
protein and small molecule interaction, biological and replica-
tion machinery mechanisms of action, are only beginning to 
be understood. Likewise, the propensity for deleterious inflam-
matory responses is episodically studied against SARS-coV-2 
antigen presentation, antigen‑specific antibody and cell medi-
ated responses contributing to protective adaptive immunity 
and the attenuation of disease severity, as well as pulmonary and 
systemic tissue destruction. comprehensive interrogation of 
the viral-human interactome, and associated chemoinformatic 
analyses (2,3) nevertheless offer hope for the identification of 
nodal intervention points across the continuum of cOVId-19 
disease (4,5). As elucidation of these phenomena will undoubt-
edly incur delays in developing appropriate pharmacological 
interventions, clinical attention is understandably focused on 
US Food and drug Administration (FdA) approved drugs 
which present putative treatments aligned to our present under-
standing of SARS-coV (the agent of 2002-2003 Guangdong 
corinavirus epidemic) and Middle East respiratory syndrome 
virus (MERS‑CoV) infections, followed by compounds in 
clinical, or even late pre-clinical investigation (6,7).
2. Virological, genomic, and host aspects related to 
COVID‑19 treatment
SARS-coV-2 is a pleomorphic, enveloped, positive-sense 
single‑stranded RNA virus [(+)ssRNA] which encodes 
15 or 16 replicate-related proteins, 4 or 5 structural proteins 
and 1-8 group-specific or accessory proteins from the 
Orthocoronavirinae subfamily, Coronaviridae family, order 
Nidovirales (8). coronaviridae are a large family that includes 
at least four viruses responsible for common colds: four human 
coronaviruses (HcoV 229E, NL63, Oc43, and HKU1) account 
for up to a third of adult upper respiratory tract infections (9). 
A phylogenetic tree of alpha-beta coronavirus is presented in 
Fig. 1.
SARS‑CoV‑2 shows great phylogenetic similarity to several 
strains of coronavirus isolated from bats in china, sharing 
88% identity with bat‑SL‑CoVZC45 and bat‑SL‑CoVZXC21 
which were isolated in Zhoushan, eastern China (10), more 
than 96% genomic similarity with BatCoV RaTG13 collected 
in Yunnan Province (11), and to a lesser extent to SARS-coV 
(approximately 79% homology). By contrast, the camelid‑orig-
inating MERS-coV shares approximately 50% homology to 
SARS-coV-2 (10).
Measuring a sizeable 29.8 kb, the SARS‑CoV‑2 genome 
is flanked by short 5' and 3' highly structured untranslated 
regions (UTRs) commonplace in RNA viruses and contains 
at least 14 open reading frames (ORFs) encoding 27 proteins 
organized in a manner typical of other coronaviruses 
(CoVs) (12) (Fig. 2). The first ORFs are translated into two 
large polyproteins (pp1a and pp1ab) cytosolically processed 
into the non-structural proteins (nsp) 1-16. These contain the 
polyprotein-processing protease nsp5, a host RNA restriction 
factor (nsp1) arresting canonical translation, and collectively 
function as the viral replicase-transcriptase complex (2) by 
rearranging rough endoplasmic reticulum (RER) membranes 
into double‑membrane vesicles (DMVs) wherein replica-
tion, transcription and virion assembly take place (13,14). 
The immunomodulatory protein nsp16 is 2'‑O‑ribose methyl 
transferase that renders the virus a toll‑like receptor (TLR) 7/8 
antagonist (15) and is believed to enhance the purported 
capacity of the virus to evade antiviral interferon-generating 
cytosolic pathogen associated molecular pattern recognition 
receptors, such as the double stranded RNA (dsRNA) sensing 
protein kinase R (PKR) and TLR3, on account of the DMV 
replication organelle structure (16). An additional protein 
of key pharmacological interest the RNA‑dependent RNA 
polymerase (RdRp) nsp12, which is the primary target of the 
so-called directly acting antiviral (dAA) drug family. The 
remaining ORFs encode the so‑called spike (S or SARS‑2‑S) 
protein responsible for virus tropism, as well as envelope I, 
nucleocapsid (N) and membrane (M) structural proteins. 
The mechanistic role of many of the remaining accessory 
proteins that are redundant to viral replication remains unde-
termined (7).
The human angiotensin-converting enzyme 2 (AcE2) cell 
surface recaptor has been confirmed as the primary cell attach-
ment factor for SARS-coV-2 (18). This single transmembrane 
domain protein is expressed at appreciable protein levels on 
terminal bronchiole as well as type I and II lung alveolar 
epithelium cells, which aligns with the primary pathology 
of cOVId-19: loss of O2 saturation due to poor pulmonary 
gas exchange. Likewise, noteworthy ACE2 levels have been 
reported among enterocytes of the small intestine, arterial, and 
venous endothelial cells, and arterial smooth muscle cells in 
most organs, as well as the vagus nerve innervating the lung, 
heart and digestive system (19,20), which mirror the diversity 
of symptoms and pathologies associated with COVID‑19: 
diarrhea, myocarditis, fatigue, encephalopathy (headaches, 
confusion, anosmia, stroke‑like symptoms, and seizures). 
Following cellular attachment, pivotal to cellular entry is 
the type II transmembrane protease serine 2 (TMPRSS2) 
which process the SARS‑CoV‑2‑S to expose a cell‑membrane 
fusion peptide (21). Once membrane fusion is achieved, 
viral RNA is released into the infected host cell to initiate 
pathogenic responses and viral replication. In a first step, the 
open reading frame 1a/b (ORF1a/b) of the viral genome is 
translated to produce the replicate proteins, after which the 
replicase-transcriptase complex dMVs are assembled. In a 
second step, the replication complex reverse-transcribes the 
positive RNA genome into full-length negative-sense RNAs, 
which in turn template the production of daughter full‑length 
genomes, and a subset of translation-focused mRNAs. These 
translation‑dedicated transcripts contain a common 5' leader 
sequence cytosolically spliced to downstream genes, which are 
added by discontinuous synthesis of minus sense subgenomic 
RNAs templating the positive RNA genome (22).
The genetic variance of SARS-coV-2 is relatively small 
compared to other RNA viruses (23), since coVs possess 
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mechanisms of transcription error correction through the 
proofreading function of nsp14 (24), a protein common to 
MERS‑CoV and SARS‑CoV, which renders them collec-
tively immune to ribavirin (25), but is also reported to 
drive recombinatory promiscuity (24). consequently, ciral 
quasi‑species are relatively suppressed within patients, and 
mutation primarily leads to single nucleotide polymorphisms 
(SNPs). Nearly 200 such mutations have been reported as of 
mid‑April 2020 (26). Based on the analysis of more than 100 
virus isolates, two main genetic variants of SARS‑CoV‑2 were 
initially identified, which are referred to by some members of 
the community as L-type and S-type, differing only by 2 SNPs. 
The L-type probably evolved from the S-type and is the more 
widespread and ‘aggressive’ variant (27). Another study with 
160 virus isolates from different countries classified the virus 
into A, B and C type, the type A being the oldest virus variant. 
Types A and c are most common in Europe and America, 
while type B predominates in Asia (26). More recently, contro-
versy over the transmission propensity of the so-called L-type 
variant, which harbours the noteworthy D614G mutation on 
SARS-coV-2-S (28), has been ascribed to mutation recurrence 
and multiple geographical introductions as elucidated through 
the analysis of 7,666 published SARS-coV-2 genomes (29). 
However, the impact of these mutations, particularly on protein 
core to the virus replication cycle such as the cell tropism- and 
attachment affinity‑defining SARS‑CoV‑2‑S remains experi-
mentally undetermined.
The current consensus among the scientific community 
remains that the main sites of SARS-coV-2 infection and 
replication are both the upper and lower respiratory tracts, 
despite viral loads being consistenly higher, and more reliable 
to detect in lower respiratory tract speciments. However, this 
position, largely driven by RT-PcR detection of SARS-coV-2 
and therefore, by extrapolation replication, does not align with 
the near dearth of AcE2 expression in the upper respiratory 
tract and oral mucosa (20). The only exceptions to these data 
are recent reports of olfactory epithelium AcE2 expression 
in mice (30) which is in line with anosmic symptomatology 
Figure 1. Phylogenetic tree of alpha-beta coronavirus.
Figure 2. Structure of RNA translation products of SARS-coV-2 and untranslated regions. Adapted from (17).
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in man, and early evidence of interferon-induced increase in 
ACE2 expression in upper respiratory tract sites, which would 
be secondary to infection and replication in either distal, or 
physiologically non-epithelial local cell types (31). curiously, 
endothelial AcE2 expression appears to be ubiquitous even 
in the upper respiratory tract (20). These findings postulate 
three hypotheses on the infection and replication cascade of 
SARS-coV-2. The simplest of these assumes direct infection of 
upper respiratory tract epithelia from fomites or large droplets 
(cough), followed by progressing infection to the lower lung 
by week 2, which would explain deteriorating clinical image 
in cases requiring hospitalization. However, this hypothesis 
would rely on transcytotic epithelial mechanisms delivering 
SARS-coV-2 to AcE2-expressing basal upper respiratory/oral 
epithelial cells or endothelia (20). Though transcytotic mecha-
nisms are not implausible (32,33), these cells would in turn 
propagate the virus locally, causing interferon-induced AcE2 
epithelial overexpression, epithelial cell infection, and luminal 
virus shedding, ultimately leading to the observations of 
low‑level detection in nasopharyngeal and oropharyngeal 
swabs by RT‑PCR. However, the immunomodulatory capacity 
of SARS-coV-2 manifest through dMVs and nsp16 (13,14,16), 
in addition to the consistently higher viral load in the lower 
respiratory tract as opposed to the relatively virus-free upper 
respiratory tract strongly disfavour this hypothesis. The second 
hypothesis would require direct infection of the olfactory 
epithelium again by fomites or droplets, local replication and 
retrograde transport to the lower lung, whereupon the virus 
would establish disease‑causing replication. However, the 
infrequent incidence of anosmia coupled to the opposite direc-
tion of travel for tracheobronchial mucocilliary clearance, 
and the need for sub-3 micron aerosol particle dimensions to 
access the alveoli that would have to be generated in the nose, 
present a formidable set of physiological barriers to the virus 
for accessing the lower lung. The last hypothesis would require 
direct infection of the lower respiratory tract through inhala-
tion of SARS-coV-2 containing aerosols, directly infecting 
the AcE2-overexpressing alveoli, sequentially driving upper 
respiratory tract infection through mucocilliary clearance 
and aerosol generation in exhaled breath. Poignantly, this 
putative infection progression sequence aligns with ACE2 
protein expression data, SARS-coV-2 levels reported by 
RT-PcR across the respiratory tracts of patients, and offers 
a mechanistic explanation for the rarity of anosmia and low 
nasopharyngeal carriage of the virus, as diminishing quanti-
ties of aerosolized virus would need to diffuse into the mucous 
found in these tissues upon exhalation. critically, data docu-
menting viral particle production in upper respiratory tract (or 
oral) epithelial or indeed endothelial cells remain elusive from 
both human and animal studies.
3. Pathogenesis
Even though the replication site of the virus is admittedly the 
lower respiratory system the virus can affect the function of 
secondary organs that also express ACE2, such as the kidney, 
GI tract, liver, and gall bladder. Typically, this results in 
symptom severity that drives patients to seek medical atten-
tion, usually by week 2 after symptom onset. However, to date 
no single clincal report has documented measurable, or at 
least appreaciable amounts of virus in the peripheral blood of 
patients admitted with COVID‑19. One possible explanation 
of the practically undetectable levels of SARS-coV-2 in blood 
might be the arrival time of patients to hospitals (week 2), by 
which time seroconversion and neutralizing antibodies are 
being generated and thus viraemia suppressed. Alternatively, 
endothelial ACE2 expression reduces blood viral load below 
the limit of detection of RT‑PCR (~15,000 copies/ml whole 
blood) by sequestering free viral particles from suspension. 
However, such extent of ACE2 expression systemically 
across endothelia is not corroborated in public protein 
expression data repositories (e.g., https://www.proteinatlas.
org/ENSG00000130234-AcE2/tissue), nor is it physiologi-
cally evidenced by the loss of endothelial barrier function 
as is common in haemorrhagic fever viral infections. Taken 
together, these findings cast doubts on hypotheses regarding 
the mechanism of transfer of SARS-coV-2 from the respira-
tory tract to the intestines (34), which is manifested through 
faecal detection of SARS-coV-2 RNA (35) and protein in 
lower GI tract (36). By stark contrast, the main sites of ACE2 
expression, i.e., the lung, GI tract, kidneys, liver and gall-
bladder, and indeed the testis in men, wherein SARS‑CoV‑2 
replication has also been documented (37), are all innervated 
by the vagus nerve.
The median time from symptom onset to acute respiratory 
distress syndrome, the principal reason for cOVId-19 patients 
seeking medical attention, is approximately 8 days; around this 
timepoint cOVId-19 appears to morph from an acute viral 
infection to what might appear to be a second attack, causing 
the patient's condition to worsen over the second week after 
symptom onset. critically, continued deterioration beyond day 
14 is associated with high mortality. Thus the disease could be 
divided into three major stages after symptom onset: in the first 
stage symptomatic patients report initially mild-to-moderate, 
but quality of life impacting non‑specific symptoms (days 0‑7) 
associated with a progressive drop in viral load; stage II, 
wherein severe dyspnoea and associated pneumonia drive 
patients to seek medical attention; and, finally stage III, a severe 
respiratory symptomatic stage potentially with high viral load, 
but most commonly characterised by runaway inflammatory 
responses associated with multiple organ failure (38,39).
Thus, the ensuing innate immune response might be 
two‑phased; instead of the early innate immunity containing 
the virus towards the developement of adaptive immunity, 
in some patients there would appear to be a loss of key 
checkpoint functions driving a secondary, damaging inflam-
matory phase. The second inflammatory phase is driven by 
the cytokine release syndrome (the so‑called ‘cytokine storm’) 
and affects patients with severe conditions. Although genetic 
differences may underpin innate response amplitude between 
individuals, viral amplification appears to ensue (40) causing 
direct or, more likely, indirect destruction of tissues affected 
by the so‑called ‘happy hypoxia’ associated with COVID‑19, 
the otherwise asymptomatic critical reduction of blood oxygen 
saturation below 95%, sometimes reportedly as low as 50%, 
i.e., well below the level normally associated with respiratory 
arrest.
The early antibody response against SARS-coV-2 
including IgA, IgM, and IgG response was examined by using 
an ELISA-based assay on the recombinant SARS-coV-2 
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protein against the recombinant proteins for the other four 
common cold-causing human coronaviruses. The median 
time to IgM and IgA antibody detection was 5 days with inter-
quartile range (IQR) 3‑6, while IgG was detected on 14 days 
(IQR 10‑18) after symptom onset, with a positive rate of 85.4, 
92.7 and 77.9%, respectively (41). In a study of 23 patients with 
COVID‑19, viral load was reported to be declining across the 
first week of illness, dropping below detection limits amongst 
most patients by week 2. With analytical sensitivity lacking 
between days 7‑10, IgG and IgM antibodies were detect-
able more reliably at approximately 10 days after symptom 
onset, with most patients seroconverting within the first 
3 weeks. Importantly, both IgG and IgM were observed to 
neutralize SARS-coV-2-N and the recaptor binding domain 
of SARS-coV-2-S (42).
Research data on late humoral response and persistence 
of neutralizing antibodies in SARS-coV-2 infection is still 
limited. A major cause for concern are reports in china, 
Japan and South Korea of patients testing still positive by 
RT‑PCR days, or even weeks after clinical discharge presum-
ably on the basis of two consecutive negative RT‑PCR results. 
Some patientsa are even reported to relapse, indicating that a 
sustained immune response may be difficult to obtain, or that 
at least humoral immunity is inadequate for infection elimina-
tion (40). Although the World Health Organization (WHO) has 
recently pronounced these observations as a consequence of 
RNA shedding from infected apoptotic epithelia in the respi-
ratory tract, corroborating data in the literature are lacking. On 
the other hand, patients who have recovered from SARS‑CoV 
have been reported to harbour potent antibody responses to 
SARS‑S protein and its receptor binding domain (RBD) for 
at least three years, indicating that RBD‑targeting vaccines 
under development might be adequately protective against 
cOVId-19 (43,44).
Another aspect meriting attention is the progressive 
lymphopenia documented during COVID‑19, which is princi-
pally manifest and most pronounced in severe cases, affecting 
cd4+ and cd8+ T cell levels, as well as B lymphocyte concen-
tration, potentially adversely affecting antibody production. 
Thus, T cell lymphopenia and associated cytokine concentra-
tions have been proposed as biomarkers of poor prognosis, with 
interleukin (IL)‑6, IL‑10, and D‑dimer continued elevation 
marking transition to a severe disease state between days 7‑14 
after symptom onset, followed by further elevation of D‑dimer, 
neutrophilia, blood urea nitrogen, and creatinine marking in the 
later, irreversible stages of disease. In contrast, IL-8 and tumor 
necrosis factor alpha (TNF-α) elevation appears to be associ-
ated and indeed peak early during the recovery phase (45,46).
4. Treatment strategies
In the absence of a clinically proven treatment for cOVId-19, 
frontline clinicians are restricted to offering supportive symp-
tomatic treatment such as oxygen therapy, steroids on a per 
case basis, fluid management, and broad‑spectrum antibiotics 
against co‑ or secondary bacterial infections (45). Beyond 
these, as with any viral disease, therapeutic intervention may 
extend to either direct acting antivirals (dAAs) or immuno-
modulatory adjuvants and substances (47). considering the 
drug discovery process, research efforts can be grouped in 
three major classifications. The first relies on the repurposing 
of approved, broad-spectrum antiviral drugs, through clinical 
trial and error. The major advantage of this approach consists 
of the clear knowledge about the drugs' metabolic profile, 
dosages needed and supported, potential side effects, and risks. 
The disadvantage of these types of drugs is represented by their 
low selectivity and, often, poor utility between virus families. 
The second strategy is based on high-throughput screening, 
in silico, in cellulo or, more recently, by means of artificial 
intelligence drug discovery, to identify approved, or, at best, 
late stage drugs with promising therapeutical effects either 
through their intended mode of action (e.g., RNA dependent 
RNA polymerase inhibition), or through their well‑described 
off‑target effects (similar to kinase inhibitor promiscuity). The 
third strategy involves identifying the molecular and patho-
logical characteristics of the disease in question, to develop 
entirely novel drugs that may target them. The advantage 
here would be the high selectivity and potentially high effi-
cacy (48). Thankfully, the 18 years of head start knowledge 
gained against SARS‑CoV‑2 on the back of the SARS‑CoV 
and MERS‑CoV outbreaks of the early 21st century, have 
resulted in an unprecedented speed by which the molecular 
mechanisms of SARS-coV-2 infection are being elucidated, 
not least because of the rapid elucidation of the genomic 
organization of SARS-coV-2. These datasets have informed 
several rational, high confidence potential therapeutic targets 
against SARS-coV-2 (10,49) (Fig. 3).
As the development of new drugs is a long and costly 
process, the urgency of the pandemic targeted early efforts 
on identifying candidate treatments among marketed drugs or 
approved, but later abandoned compounds. drug repurposing, 
also known as drug repositioning, is one of the best solutions to 
identify therapeutic solutions for cOVId-19 in a time-critical 
fashion (50).
Blocking virus cell entry. Penetration of host cells is an obliga-
tory step in the life of any virus rendering it a powerful target 
for drug development (51). The discovery of the intrinsic 
mechanism of SARS-coV-2-S to mediate cell entry focused 
efforts on ACE2 and the whole renin‑angiotensin‑aldosterone 
system (RAAS) (18,51). AcE2 is monocarboxypeptidase that 
hydrolyzes the bond between the carboxyl‑terminal phenylala-
nine and proline in angiotensin II (Ang1-8) generating Ang1-7, 
a physiological antagonist of Ang1‑8 with vasodilator and 
anti‑inflammatory properties (52). Considering these effects, 
a soluble recombinant human ACE2 (rhACE2) was devel-
oped under the name APN01 (known also as GSK2586881) 
and evaluated in patients with pulmonary arterial hyper-
tension (53) and acute pulmonary injury (54). In healthy 
volunteers rhACE2 was administered intravenously in doses 
from 100 to 1,200 µg/kg and was generally well‑tolerated, 
with no significant effect on blood pressure and heart rate, and 
with only mild or moderate adverse events reported (52).
SARS-coV-2-S engages AcE2 as the entry receptor in 
a similar way as the homologous SARS‑CoV spike protein. 
The expression and distribution of the AcE2 on alveolar 
epithelial cells is consistent with the dry cough and dyspnea 
experienced by the patients. consequently, it is anticipated that 
rhAcE2 may act as a competitive interceptor of SARS-coV-2 
thereby reducing cell penetration and offering protection 
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against infection (55). A randomized placebo-controlled study 
(NcT04335136) is scheduled to test rhAcE2 in SARS-coV-2 
patients (56). Furthermore, several peptide derivatives of 
ACE2 were designed using molecular dynamics simulations as 
potential decoys that could be used as future inhaled therapeu-
tics (57). However, drug development history (inhaled insulin, 
Exubera) denotes the brief residence time of soluble proteins 
in the respiratory lumen, necessitating modifications (58) that 
would sustain rhACE2 decoy potency at the primary infection 
site of interest for SARS-coV-2, the respiratory epithelium.
Another strategy focused on AcE2 is based on the hypoth-
esis that AcE2 activity is reduced by SARS-coV-2-S, exposing 
the organism to higher levels of Ang1‑8 which increases alveolar 
permeability and causes lung injury (59). Two compounds, resor-
cinolnaphthalein and 1-[(2-dimethylamino)ethylamino]-4-(hydro
xymethyl)-7-[(4-methylphenyl)sulfonyloxy]-9H-xanthene-9-one, 
were identified in a large docking study as ACE2 activators and 
were demonstrated to enhance ACE2 activity in a dose‑depen-
dent manner, albeit with half‑maximal effective concentration 
(Ec50) values of 19.5±0.4 and 20.1±0.8 µM, respectively (60). 
diminazene aceturate is a veterinary-approved antitrypano-
somal drug that similarly activates AcE2 at comparable in vitro 
Ec50, rendering protective effects in cardiovascular and type 1 
diabetes experimental models (61,62). A recent review study 
presents the toxic effect of diminazene aceturate on the nervous 
system of some animals, but provides evidence that it was safe 
in thousands of trypanosomiasis patients from Uganda (62). 
These compounds could be a potential therapy in patients with 
SARS-coV-2, provided topical dosing and pharmacology afford 
adequate activation of respiratory AcE2.
Likewise, use of Ang1‑8 receptor 1 (AT1) antagonists to 
reduce the aggressiveness and mortality of SARS-coV-2 
infection based on two mechanisms, the blockade of the effects 
of excess Ang1-8, and the upregulation of AcE2 (63). Several 
clinical studies are underway to asses various AT1 antagonists: 
losartan 25 mg once daily (NcT04335123, NcT04328012, 
and NcT04311177) or 50 mg daily (NcT04312009), losartan 
100 mg once daily alone or in combination with aspirin 
150 mg once daily or simvastatin 80 mg once daily in an 
eight arms factorial trial (NcT04343001), telmisartan 80 mg 
twice daily (NCT04355936), valsartan 80 mg up to 160 mg 
(NcT04335786) (56).
camostat is an orally active serine protease inhibitor of 
trypsin and various inflammatory proteinases including 
plasmin, kallikrein, thrombin and urokinase (64). It is 
approved clinically as mesylate salt in Japan, but not Europe 
or the USA, for the treatment of chronic pancreatitis and 
postoperative reflux esophagitis due to its ability to inactivate 
trypsin and prevent autodigestion (65). camostat mesylate has 
demonstrated inhibitory activity against TMPRSS2 and other 
cell-surface proteases involved in SARS-coV activation (66). 
Indeed TMPRSS2 emerged as a promising antiviral drug 
target after it was identified to have a pivotal role for viral 
pathogenesis of monobasic H1N1, H3N2 and H7N9 influ-
enza A viruses (67).
Exposure of human bronchial epithelial calu-3 cells to 
10 µM camostat mesylate was reported to cause a 10‑fold 
decrease in SARS-coV viral entry and a 13-fold decrease 
in SARS-coV replication (66). Although from a virology 
perspective such inhibitory effects are considered mediocre, 
animal experiments in BALB/c mice at 30 mg/k administered 
orally twice daily for 9 days starting 10 h before SARS‑CoV 
inoculation increased survival rate to 60 vs. 0% for untreated 
animals (65). Similarly, Calu‑3 cells pre‑incubated with 
camostat mesylate at very high concentrations (100 µM) 
before infection with SARS‑CoV‑2 significantly reduced, 
but failed to abrogate Calu‑3 infection with SARS‑CoV‑2 
as measured by SARS‑CoV‑2‑specific RT‑PCR (21). Thus, 
a randomized, placebo-controlled, phase IIa clinical 
trial (NcT04321096) is evaluating camostat mesylate at 
200 mg x 3/day for 5 days as treatment for SARS-coV-2. 
However, it is noteworthy that the study design of this trial 
fails to meet the pre-treatment or, at least, early treatment 
requirement common to most efficacious antivirals and 
indeed the in vitro and in vivo performance requirements 
exhibited previously. Elsewhere, the CLOCC‑2020 clinical 
study (NCT04338906) will evaluate the efficacy and safety 
of camostat mesylate in combination with the controversial 
agent hydroxychloroquine in hospitalized patients with 
moderate cOVId-19 infection (56).
Nafamostat, a chemical analog of camostat, has potent 
inhibitory effects on several types of serine proteases 
including trypsin, thrombin and plasmin (68) and was 
identified to effectively reduce the MERS‑CoV viral entry 
Figure 3. Major therapeutical strategies in cOVId-19.
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in calu-3 cells at the physiologically relevant concentra-
tion of 1 nM (69). Nafamostat at 100 µM demonstrated 
promising inhibitory effects against SARS-coV-2 infec-
tion of Vero E6 cells (70), but it is anticipated that its very 
short half‑life (71) significantly hinders clinical utility in 
preventing SARS-coV-2 infection.
Bromhexine, a widely used mucolytic cough medicine, was 
identified as a TMPRSS2 inhibitor in a screening on various 
chemical libraries, including over 1,200 FdA approved drugs. 
With an Ic50 of 0.75 µM, inhibition was reported as selective, 
with low effects on the related hepsin and matriptase prote-
ases (72). However, preliminary data on influenza‑infected 
Calu‑3 cells treated with bromhexine showed no inhibi-
tory effect (73). Despite a lack of in vitro or in vivo data on 
SARS-coV-2, it has been proposed as a solution for cOVId-19 
patients based on its effect on TMPRSS2 and favorable phar-
macokinetic and safety profile (74). Several clinical trials are 
registered to evaluate bromhexine as prophylaxis or therapy 
in cOVId-19 patients using various drug combinations 
(NcT04355026, NcT04340349, NcT04273763) (56).
Aprotinin is a natural 58 amino acid peptide and 
a serine protease inhibitor that blocks fibrinolysis and 
reduces bleeding. It demonstrated significant effects against 
influenza viruses (75). Preliminary research reports have 
demonstrated that in caco2 cells aprotinin is more potent 
against SARS-coV-2 (Ec50 = 22.9 KIU/ml) than against 
SARS-coV (Ec50 = 118 KIU/ml) cytopathogenic effects (76) 
as measured in kallikrein inactivator units (KIU). To this 
date, no clinical test has been registered in clinical Trials 
databases (56).
SARS-coV nucleocapsid (protein N) binds to cyclophilin 
A, which subsequently interacts with a member of the immu-
noglobulin family of receptors, HAb18G/cd147, on the cell 
membrane leading to viral cell invasion (77), in a mechanism 
similar with that of HIV‑1 virus (78). Based on this model, 
a humanized anti‑CD147 antibody was clinically tested in 
17 patients with SARS‑CoV‑2 (NCT04275245) and published 
in a preliminary fashion (79). Whilst the results are interesting, 
interpretation should be approach with caution as the source 
and characteristics of the antibody, ‘meplazumab’, are missing, 
and the number of tested patients is very low.
clathrin-mediated endocytosis is another mechanism 
described for SARS-coV cell invasion and possibly utilized 
by SARS-coV-2. chlorpromazine inhibits the relocation of 
clathrin and the adaptor protein 2 (AP2) from the cell surface, 
significantly inhibiting SARS‑CoV entry into HepG2 cells at 
the relatively high concentration of 20 µM (80). Unfortunately, 
it showed no significant effect on the SARS‑CoV‑2 cytopathic 
effects in Vero E6 cells when tested at 100 µM (81), yet a 
clinical trial is scheduled to test the effect of 25 mg chlor-
promazine administrated intravenously every 6 h for 1 week 
(NcT04354805) (56).
An artificial intelligence method identified members of 
the numb‑associated kinases (NAK) family as potential thera-
peutic targets against SARS-coV-2 (82). The AP2-associated 
protein kinase 1 (AAK1) is an important member of NAK that 
binds to clathrin and phosphorylates the medium subunit of 
AP2, playing an important role in regulating clathrin-medi-
ated endocytosis (83,84) and its inhibition was demonstrated 
to reduce the infectivity of a wide range of viruses (82). The 
chemically related pyrazole-pyrolopyrimidine derivatives 
baricitinib and ruxolitinib are clinically approved Janus 
kinase (JAK) inhibitors with important inhibitory effects on 
AAK1 (85), likewise predicted to reduce SARS‑CoV‑2 infec-
tion (82). A clinical trial (NcT04348071) is programmed to 
evaluate ruxolitinib in patients receiving 10 mg twice daily for 
14 days and a similar trial (NCT04340232) will test baricitinib 
administered 2 mg once daily for 14 days (56).
The role of cathepsins in coronavirus entry has been estab-
lished for SARS-coV and MERS-coV. In order to investigate 
their role in SARS‑CoV‑2 cell entry a pseudovirus model was 
tested in ACE2‑expressing 293 cells. While cell treatment with 
the cysteine protease cathepsin B inhibitor CA‑074 (30 µM) 
had no significant effect, cathepsin L inhibitor (SID 26681509, 
2 µM) treatment reduced viral entry up to 76%. An inhibitory 
effect close to 93% was reached after treatment with E64d 
(30 µM), an inhibitor of calpain and cathepsin B, H and L (86). 
cathepsin L is an attractive target for drug development in 
several diseases, but despite all the efforts, no cathepsin L 
inhibitor has advanced to clinical trials (87) making future 
cathepsin L-based SARS-coV-2 therapies improbable.
Interfering with the endocytic pathway. Most viruses use 
endocytic entry mechanisms and for the majority of them, 
a reduction of pH serves as a cell penetration trigger (88). 
Earlier studies have described that endocytic pH modification 
suppresses viral replication and may also have a virucidal 
effect. Such a minimal pH value change, with no negative 
impact on the patient's health status, could be achieved by 
administering a simple small molecule with hydrophobic weak 
base properties, like ammonium chloride, which would lead to 
endocellular alkalosis by accumulating in lysosomes following 
diffusion through plasma and lysosomal membranes. Weak 
bases and ionophores, like ammonium chloride, chloroquine, 
or monensin are frequently used in experimental studies of 
viral cell penetration mechanisms (89). Ammonium chloride 
treatment strongly inhibited the entry of pseudotypes bearing 
SARS‑2‑S in 293T cells lacking TMPRSS2, but was less effi-
cient in caco-2 cells (TMPRSS2+) (21).
Chloroquine, chemically known as 7‑chloro‑4‑((4‑(diethy
lamino)-1-methyl butyl)amino)quinoline, is a 9-aminoquino-
line widely used for the treatment of malaria, amebiasis and 
several auto-immune diseases (90) recently proposed to be 
efficient in inhibiting SARS‑CoV‑2 in infected cells (70,91). 
chloroquine has already demonstrated in the past in vitro 
anti-viral activity against several types of both RNA and 
DNA viruses, such as rabies virus, poliovirus, several influ-
enza virus types, hepatitis A, B and C viruses, Dengue virus, 
Zika virus, and many others (92), as well as SARS‑CoV (93) 
and MERS-coV (94). The general anti-viral mechanism of 
action relates to the ability of chloroquine, as a weak base, to 
increase the endosomal pH required for viral/host cell fusion, 
preventing endocytosis, and to interfere with viral particles 
bound to the cell surface membrane (95). Additionally, in 
the case of SARS-coV and SARS-coV-2, chloroquine is 
proposed to inhibit the glycosylation of AcE2 receptor chains, 
thus limiting ligand recognition of these receptors, rendering 
the viral spike protein unable to mediate cell entry (92).
In light of the new pandemic, several clinical trials have 
been conducted in different countries in order to test the safety 
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and efficacy of chloroquine phosphate in treating SARS‑CoV‑2 
patients (96), with results confirming a significant improvement 
when compared to control groups, as in the case of clinical 
trial ChiCTR2000029609 (97). When confronted with the 
recent cOVId-19 crisis in china, chloroquine has even been 
included in the national treatment guidelines, with Chinese 
clinicians recommending 500 mg chloroquine twice daily for 
10 days for the treatment of mild, moderate and severe cases 
of SARS‑CoV‑2‑related pneumonia with no contraindications 
to the drug (98).
Hydroxychloroquine is a less-toxic derivative of chloro-
quine also used as an anti-malarial and in the management of 
auto-immune disease, proposed through in vitro studies to act 
also on SARS-coV-2 infected cells (91). In Vero E6 models 
hydroxychloroquine presented a better antiviral effect with 
Ec50 values of 6.14 µM (after 24 h) and 0.72 µM (after 48 h), 
compared with chloroquine values of 23.90 µM (24 h) and 
5.47 µM (48 h) (91).
Similar to chloroquine in many aspects with the exception 
of a better pharmacotoxicological profile, hydroxychloroquine 
is more frequently used instead of chloroquine in cOVId-19 
clinical trials (99). Several studies confirmed hydroxychloro-
quine sulfate administration to be significantly associated with 
a reduction of the viral load in SARS-coV-2 infected patients, 
as in the case of the chinese randomized clinical trial reported 
by chen et al (chicTR2000029559) (100) and Gautret et al, 
who also reported after 6 days of treatment apparently signifi-
cant benefits compared to negative controls when administering 
daily 600 mg hydroxychloroquine in association with azithro-
mycin, where necessary (101). The drug is currently perceived 
in certain quarters to be more promising than chloroquine as a 
cOVId-19 treatment due to the reduced probability of causing 
retinopathy, psychiatric disorders, or severe cardiovascular 
adverse effects such as arrhythmia (99); however, self‑medi-
cation using both drugs is unadvisable, as 9-aminoquinolines 
possess a narrow therapeutic window (102) and are associated 
with QT prologation. Currently, larger studies with a more 
flexible design investigate the effect of hydroxychloroquine, 
with the Solidarity study (EudraCT no. 2020‑000982‑18) and 
the discovery study (NcT04315948) randomizing treatment of 
SARS-coV-2-infected patients using different antiviral drugs, 
including hydroxychloroquine (103). However, preliminary 
reports are highlighting a 2.61 adjusted hazard ratio of death 
among COVID‑19 patients treated with hydroxychloroquine 
alone in the absence of azithromycin, and no reduction in the 
risk of mechanical ventilation (104).
Blocking polyprotein posttranslational processing. Another 
promising strategy of treatment appears to be interfering with 
viral replication, especially by acting at key points following 
translation. After synthesis, the two newly‑formed viral poly-
proteins pp1a and pp1b require for posttranslational processing 
two important proteinases encoded in these chains of amino 
acids: papain‑like proteinase, PLpro, and chymotrypsin‑like 
proteinase, 3cLpro, often referred to as the main protease or 
Mpro (3). The activity of these two cysteine proteases is essen-
tial for generating the 16 non-structural proteins, critical to 
the formation of the replicase complex, and it is known that 
inhibiting the activity of either of these two proteases affects 
the replication of SARS-coV-2 (3,105).
Several inhibitors acting on SARS-coV main protease, 
which displays 96% similarity to the SARS‑CoV‑2 
Mpro (106), have recently been synthesized and tested both 
in enzymatic assays and in cell lines, showing promise 
for developing future drugs. Recently, Zhang et al, after 
structure-based drug design and optimization of different 
dipeptide α‑ketoamides, derived several potential Mpro 
inhibitors, of which (S)‑N‑Benzyl‑3‑((S)-2-cinnamamido-3-
cyclohexylpropanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)
butanamide (referred to as 11r) displayed physiologically rele-
vant (nM) antiviral activity against MERS-coV and SARS-coV 
in hepatic (Huh7) but not routine virology (Vero E6) cell lines, 
as well as good inhibition of the SARS‑CoV protease in enzy-
matic assays (107). Based on previous research, the same study 
group obtained a pyridone-containing α‑ketoamide deriva-
tive of 11r, a compound (referred to as 13b) with even lower 
sub-micromolar concentrations against SARS-coV-2 Mpro in 
enzymatic assays, with half‑maximal inhibitory concentra-
tion (Ic50) 0.67±0.18 µM, and low‑micromolar EC50 values 
(4-5 µM) in calu-3 cells, further obtaining favorable results 
in mouse studies in terms of pharmacokinetic parameters, 
reflecting lung tropism after either subcutaneous or topical 
administration (108).
drug repurposing appears to be another interesting method 
of identification of Mpro inhibitors. Most notable drugs showing 
inhibition of the main protease of SARS‑COV‑2 were found to 
be several anti-retroviral agents approved for HIV-1 treatment.
Lopinavir is a selective HIV-1 protease inhibitor orally 
administered in combination with ritonavir, a CYP3A4 
inhibitor used to increase its plasma concentration and clinical 
efficacy (109). Lopinavir was tested against SARS‑CoV and 
showed a moderate activity in Vero‑E6 cells (110). In a prelim-
inary, not yet peer‑reviewed, study in Vero E6 cells, lopinavir 
showed a mediocre EC50 = 5.73 µM against SARS-coV-2 (111). 
A recent clinical trial investigating the safety and efficacy of 
lopinavir (400 mg) and ritonavir (100 mg) effect in 99 patients 
infected with SARS‑CoV‑2 has already ended, unfortunately 
concluding that the administration of these drugs showed no 
significant benefit comparing to current standard care (112). 
The ineffectiveness of this combination could be explained 
by the delayed treatment initiation, the median time from 
symptoms identification to therapy onset being 13 days (51). 
Whether the ineffectiveness of the treatment was due to the 
late therapy start or because of low efficient concentrations at 
the site of action remains to be explored.
The clinical use of lopinavir/ritonavir is additionally 
linked to nausea and diarrhea (up to 28%) as well as hepato-
toxic effects (2-10%). despite the limited data to support use 
in the treatment of cOVId-19, there is an important number 
of clinical studies registered to test the lopinavir (400 mg) and 
ritonavir (100 mg) coformulation alone or in combination with 
hydroxychloroquine or interferon (51,56).
Other HIV-1 protease inhibitors, such as amprenavir, 
tipranavir, saquinavir, ritonavir, nelfinavir, indinavir, darunavir, 
and atazanavir that have been predicted to inhibit SARS-coV-2 
Mpro (113) were also tested on Vero E6 cells infected to 
SARS‑CoV‑2. Among these, nelfinavir was observed to be the 
most efficient, with a mediocre EC50 of 1.13 µM suppressing 
viral replication in the post-entry step (111). In a similar 
study on SARS‑CoV, nelfinavir inhibited the viral replication 
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at non‑toxic doses with a selectivity index (SI) close to 300, 
while ritonavir, lopinavir, saquinavir, and indinavir, did not 
have a significant effect (114). Saquinavir and tipranavir 
showed mediocre replication inhibition against SARS‑CoV‑2 
in cell lines (Ec50 = 8.83 µM, respectively 13.34), although 
with a lower selectivity index, while amprenavir, darunavir 
and indinavir had low effects on viral replication with EC50 
values over 30 µM (111). Another preprint publication reports 
the SARS-coV-2 viral replication inhibition by atazanavir 
with EC50 values of 2.0±0.12 µM (115).
No clinical study is registered in the clinical Trials 
database, nor in the chinese clinical Trial Registry to test 
atazanavir, nelfinavir, tipranavir, or saquinavir as COVID‑19 
therapies. The clinical trials NcT04252274, NTc04303299 
and NCT04366089 will test darunavir in association with 
other antivirals (56).
Targeting viral RNA‑dependent RNA polymerase. The 
RNA-dependent RNA polymerase (RdRp) is the central 
subunit of the RNA synthesizing process for all positive-strand 
RNA viruses and therefore an attractive target for antiviral 
inhibitors. In SARS-coV-2 nsp12 functions as RdRp (116) 
and plays a central role in the viral replication and transcrip-
tion by catalyzing the synthesis of viral RNA, assisted by 
nsp7 and nsp8 that serve as co-factors (117). The polymerase 
of RNA viruses is prone to replication mistakes, lacking the 
proofreading capacity of its analog from dNA viruses. This 
high mutation rate (10-3 to 10-5 mutations/nucleotide/round of 
replication) enables RNA viruses to better adapt to environ-
mental changes, but also introduces damaging mutations that 
corrupt essential functions, a process called lethal mutagen-
esis (118,119).
In CoVs, nsp14 has both 3'‑5' exoribonuclease (ExoN) 
and guanine-N7-methyltransferase (N7-MTase) functions. 
ExoN can hydrolyze RNA acting as a proofreading enzyme 
that is capable of removing mismatched nucleotides (120). 
Targeting viral RNA-dependent RNA polymerase has proven 
a successful strategy in treating various viral infections (121), 
but is difficult in the case of coVs because of the ExoN 
activity (116,119). Importantly, the catalytic site of RdRp 
shares structural similarities with the hepatitis C virus (HCV) 
ns5b RdRp (117), introducing the prospect of repurposing 
ns5b HcV antivirals as cOVId-19 therapies. The results of 
a docking study indicate that tenofovir and sofosbuvir, two 
approved HcV antivirals, can bind tightly to SARS-coV-2 
RdRp (122). Still, these results should be view with caution 
considering their effect could be theoretically easily reversed 
by nsp14 activity. It is thus hypothesized that finding inhibitors 
of ExoN activity could be a future direction for cOVId-19 
therapeutics (119).
A number of compounds with proven inhibitory effects 
on other virus RdRps were tested against SARS‑CoV and 
SARS-coV-2, triaging some of them to clinical evaluation. 
Ribavirin has the advantage of being clinically approved, but 
is associated with important side effects and low efficacy. By 
contrast, remdesivir, and to a lesser extent, favipiravir and 
galidesivir, look like the most promising RdRp inhibitors for a 
future cOVId-19 solution.
Remdesivir, formally known as GS‑5734, is a 2‑ethyl-
butyl-L-alaninate phosphoramidate prodrug that generates the 
active compound, GS-441524, a 4-amino-5-cyano-pyrrolotri-
azine analog of adenosine (123). Remdesivir is metabolized 
more efficiently than its metabolite GS‑441524 into the active 
nucleoside triphosphate that function as a chain-terminating 
nucleotide analog blocking RdRp (116). Remdesivir is not 
approved by the FdA and not by the European Medicines 
Agency (EMA), but recently received FdA emergency use 
authorization for the treatment of cOVId-19 on the basis of 
reduced hospitalisation time (124). However, this outcome 
is not without controversy as the trial primary endpoint was 
altered days before outcome announcement, raising important 
concerns with respect to utility under the purported mecha-
nism of action. Given the structural similarity of remdesivir 
to naturally occurring 2'‑O‑methyl nucleoside analogues, 
antagonists of toll like receptor 7, and the initiation of treat-
ment with the pre‑symptomatic/early symptomatic optimal 
treatment window, it is postulated remdesivir may actually 
affect immunosuppression of cytokine storm syndrome, as 
opposed to directly acting antiviral effects.
Remdesivir was developed to treat Ebola virus infection, but 
demonstrated a broad antiviral spectrum against SARS-coV, 
MERS-coV, and various other RNA viruses (116). In Vero E6 
cells infected with SARS‑CoV‑2, remdesivir potently blocked 
virus infection at high nanomolar concentrations with an EC50 
value of 0.77 µM demonstrating a low toxicity as the half‑cyto-
toxic concentration was reported to be above 100 µM (70). 
A separate study, however, estimated EC50 at 26.90 µM (81). 
On the other hand, in caco2 cells remdesivir inhibited 
SARS‑CoV‑2 cytopathogenic effects with an EC50 value of 
0.23 µM (70). The protective effect was increased 10‑fold by 
the addition of 8 µM of omeprazole. Omeprazole alone has 
also demonstrated anti-SARS-coV-2 protective effects, but 
at physiologically irrelevant concentrations (Ec50 = 34 µM), 
substantially above those used in clinical practice. These 
results are presented in a yet to be peer‑reviewed preprint (76).
Remdesivir was clinically tested in 175 patients in 2018 
during the Ebola outbreak in the Democratic Republic of 
congo by intravenous administration of 200 mg on day 1 
followed by daily maintenance doses of 100 mg from day 2 
and continuing for 9 to 13 days. In pediatric patients, the 
doses were adjusted based on body weight. The study revealed 
a favorable safety profile with higher mean levels of creati-
nine and aspartate aminotransferase but failed to achieve its 
primary endpoint (125).
A case report of the first COVID‑19 patient identified in 
the U.S. presents their treatment with intravenous remdesivir 
on the seventh day of hospitalization and the improvement of 
their condition afterward (126). A similar case report described 
the remdesivir treatment of three hospitalized patients under 
compassionate use protocol. The patient described as number  6 
was the same as the first case report. All three patients toler-
ated the remdesivir treatment, with transient gastrointestinal 
symptoms and a serum aminotransferase elevation (127). The 
administered doses were not mentioned in the article.
A randomized, double-blind, placebo-controlled clinical 
study (NCT04257656) on confirmed SARS‑CoV‑2 patients 
found that remdesivir (n=158, vs. 79 placebo) intravenous 
administration of a 200 mg loading dose on day 1 followed by 
100 mg daily as maintenance doses, up to a 10 days, produced 
no significant difference in time to clinical improvement. 
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The 28‑day mortality was similar between the remdesivir 
group (14%) compared to placebo (13%). However, remdesivir 
reduced the time to clinical improvement compared to placebo 
with a median of 18 vs. 23 days in the placebo group. The 
study reported no significant impact of remdesivir use on 
viral load measured on nasopharyngeal and oropharyngeal 
swabs, implying either no direct acting antiviral effect, or 
an unexpectedly long SARS-coV-2 genome half-life (128). 
This result should be analyzed considering the long average 
time (10-11 days) from symptom onset to treatment start. We 
identified a number of other clinical trials that are trying to 
evaluate the antiviral activity of remdesivir in cOVId-19 
patients (NcT04252664, NcT04292899, NcT04292730, 
NcT04302766, NcT04323761, NcT04280705, NcT04321616, 
NcT04315948, NcT04314817, NcT04349410) using the same 
doses as NcT04257656 (56).
Favipiravir (6‑fluoro‑3‑hydroxy‑2‑pyrazinecarboxamide), 
also known as T‑705, was developed as a structural analog 
of 3-hydroxy-2-pyrazinecarboxamide (T-1105) compound 
identified in an in vitro anti-influenza virus activity drug 
screening (129). Favipiravir is a prodrug that is activated by 
cellular enzyme phosphoribosylation to favipiravir-ribofura-
nosyl‑5'‑triphosphate (favipiravir‑RTP) (130). It is reported 
to selectively and potently inhibit the RNA-dependent RNA 
polymerase of a broad range of RNA viruses: influenza 
viruses, arenaviruses, bunyaviruses, noroviruses, flavivi-
ruses and filoviruses (131). Favipiravir‑RTP functions as a 
guanosine and adenosine analog, its antiviral activity being 
significantly inhibited by purine nucleotides and nucleosides, 
but not by pyrimidine nucleotides in an MdcK cell model. 
Yet favipiravir and its ribofuranosyl‑5'‑monophosphate 
showed no significant inhibitory effect on influenza virus 
RNA polymerase (100 µM). Favipiravir has a similar structure 
and also a related antiviral spectrum as ribavirin increasing 
the lethal mutations in the viral genome; this activity raises 
concerns about teratogen risk potential (131). The phar-
macokinetic profile was characterized in Japanese healthy 
volunteers to indicate a short half-life of 2 to 5.5 h and urinary 
excretion in the form of the inactive 5-hydroxy-metabolite 
(T‑705M1) (132). Because of its teratogenicity and embryo-
toxicity risks, favipiravir was approved in Japan with strict 
regulations for use only in epidemics (133).
Similar to remdesivir, favipiravir blocked SARS‑CoV‑2 
viral infection in Vero E6 cells, but at almost 80-fold higher 
concentrations, with a calculated EC50 value of 61.88 µM (70). 
The results of an open-label comparative controlled study of 
patients with COVID‑19 (ChiCTR2000029600) indicated that 
patients (n=35) receiving favipiravir (1,600 mg x 2, day 1 and 
600 mg x 2, days 2-14) had faster viral clearance and better chest 
imaging changes than those (n=45) treated for 14 days with 
lopinavir (400 mg x 2) and ritonavir (100 mg x 2). Both groups 
also received aerosol inhalation of 5 million U IFN-α twice 
daily (134). Several clinical trials are registered to test favipi-
ravir in cOVId-19 patients (NcT04358549, NcT04346628, 
NcT04310228, NcT04349241, NcT04336904, NcT04319900, 
NcT04359615, NcT04333589, NcT04303299, NcT04351295, 
NcT04356495, NcT04345419) administered orally at a 
loading dose of 3,200 up to 3,600 mg (1,600-1,800 mg at 12 h) 
on day‑1, followed by 1,200 to 1,800 mg maintenance dose 
(600-800 mg at 12 h) on days 2-10 (56).
Galidesivir, known also as BCX4430, is an adenosine 
c-nucleoside analog similar to remdesivir, but has a nitrogen 
replacing the oxygen in the ribose ring. It is converted in the 
cell to the corresponding triphosphate nucleotide and after 
the pyrophosphate's cleavage to galidesivir monophosphate 
is incorporated into nascent viral RNA, blocking viral 
RNA-dependent RNA polymerase chain extension (135,136). 
It was reported to be active against a wide range of viruses 
in cell and animal models (137). However, in a HeLa cell 
model of SARS-coV infection, galidesivir had an Ec50 value 
of 57.7 µM (135). considering the high similarity of nsp12 in 
SARS‑CoV‑2 and SARS‑CoV (12), it was evaluated in Vero 
E6 cells against SARS-coV-2, but the inhibition of viral 
replication was low at 100 µM (81). Nevertheless, a clinical 
placebo‑controlled, randomized study (NCT03891420) will 
test galidesivir administered intravenously at 12 h intervals for 
7 days in cOVId-19 patients (56).
A ribonucleoside derivative, β-d-N4-hydroxycytidine 
(known also as NHC or EIDD‑1931), was reported to demon-
strate potent inhibitory effects on MERS-coV, SARS-coV, and 
SARS‑CoV‑2 in Calu‑3 and human airway epithelial (HAE) 
cells. Encouragingly, NHc inhibited SARS-coV-2 infection 
in Vero E6 cells with EC50 values of 0.3 µM and a value of 
0.08 µM in calu-3 cells. The isopropyl ester of the prodrug 
NHC, EIDD‑2801, was evaluated in C57BL/6 mice infected 
with a murine adapted SARS‑CoV to reduce significantly the 
viral titer and associated infection symptoms when adminis-
tered in doses of 500 mg/kg. The antiviral mechanism of action 
proposes the inhibition of RdRp, with the effect of NHC being 
only slightly affected by ExoN proofreading activity (138,139). 
despite the potent antiviral profile of EIdd-2801 and its 
advantage of oral administration development for cOVId, use 
is hindered by the lack of any clinical data.
Ribavirin (1-β-d-ribofuranosyl-1,2,4-triazole-3-carbox
amide) is a broad-spectrum antiviral agent clinically used 
primarily for treating hepatitis c. The antiviral mechanism 
is complex, the most important effects being the inhibition of 
human cells inosine monophosphate dehydrogenase (IMPdH) 
by the monophosphate derivative of the drug, and the incorpo-
ration of ribavirin 5'‑triphosphate in the nascent viral genome 
by RdRp (25). Both ribavirin and favipiravir act as guanine 
analogs due to their carboxamide group that attaches to cyto-
sine by hydrogen bonds (137).
In cell models of SARS-coV infection ribavirin had a 
limited effect on viral replication (110). Similarly high concen-
trations are needed to block SARS‑CoV‑2 viral infection in 
Vero E6 cells (Ec50 = 109.5 µM) (70) limiting clinical poten-
tial against cOVId-19. The resistance of SARS-coV and 
SARS‑CoV‑2 to ribavirin is produced by ExoN's proofreading 
activity during virus replication (119).
A systematic review of the therapies tested in the SARS‑CoV 
outbreak of 2002‑2003 found that among the 20 studies on 
ribavirin, results were inconclusive, with no discernible clinical 
differences to other treatments. The review highlights various 
toxic effects presented by several studies, the most frequent 
being hemolytic anemia and liver dysfunction (140). The high 
doses needed to reduce the viral replication highlight impor-
tant toxic effects limiting the therapeutic potential of ribavirin 
treatments in cOVId-19 cases. despite these reservations, an 
open-label, non-randomized, clinical trial (NcT04356677) is 
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programmed to test aerosolised administration of ribavirin 
twice daily for up to 6 days at 50 mg/ml or 100 mg/ml concen-
trations (56). A combination of lopinavir (400 mg), ritonavir 
(100 mg), ribavirin (400 mg), and IFN-β 1b (0.25 mg) is addi-
tionally under evaluation (NcT04276688) (56).
Targeting cellular signaling pathways. Viruses highjack host 
cell‑signaling pathways, redirecting cellular processes in favor 
of their survival and replication, interfering with normal cell 
metabolism, survival, by interrupting transcription and repli-
cation (141). There are complex and not completely understood 
mechanisms of viral interference with cell signaling pathways. 
In the case of SARS-coV-2, precise information is scarce 
and amplified by the large number of proteins of unknown 
function encoded in the virus genome, but research on new 
potential therapies can successfully use knowledge gained on 
the related SARS‑CoV and MERS‑CoV outbreak pathogens.
In cells infected with MERS‑CoV perturbation of several 
regulatory kinases was detected, such as the increased phos-
phorylation of Akt1 and mTOR, modifications that have been 
linked to a decrease in autophagy (142). Thus, the virus is 
believed to block autophagy through a complex mechanism 
dependent on viral nsp6 that involves phosphorylation of 
S‑phase kinase‑associated protein 2 (SPK2) by a complex 
involving FK506‑binding protein 51 (FKBP51), PH domain 
leucine-rich repeat-containing protein phosphatases (PHLPP), 
Akt, and Beclin1 (BECN1). The activated SPK2 promotes 
the ubiquitination of BECN1 leading to its proteasomal 
degradation and inhibition of autophagy (103). A yet to be 
peer‑reviewed report has proposed that SARS‑CoV‑2 infec-
tion may strongly reduce autophagic flux in experimental 
models of human bronchial epithelial cells NcI-H1299 and 
VeroFM cells (143). The analysis of Vero E6 cells infected 
with SARS‑CoV revealed higher levels of Akt phosphory-
lated at serine 473 (S473) residue, but not at threonine 308 
(T308) (144). The anti‑apoptotic effect of Akt depends on 
both S473 and T308 phosphorylation (145) explaining low 
anti-apoptotic response to SARS-coV infection (144). These 
observations highlight the potential of targeting SKP2 or the 
PI3K/AKT/mTOR pathway.
MK-2206 is a selective and highly potent inhibitor of all 
three Akt isoforms, currently under clinical evaluation against 
various oncologic diseases (145). It reduced SARS-coV-2 
proliferation in VeroFM cells with a noteworthy EC50 value 
of 0.09 µM measured after 24 h in plaque-forming units (143). 
This antiviral potential of MK-2206 expands upon the previ-
ously reported activity on influenza pH1N1 at EC50 values in 
the micromolar range (146).
Several protein kinase inhibitors targeting the ERK/MAPK 
and PI3K/AKT/mTOR signaling pathways were tested in Huh7 
cells infected with MERS‑CoV. Pretreatment with 10 µM 
sirolimus (also known as rapamycin), an inhibitor of mTOR, 
reduced viral infection by a mediocre 61%, while postinfection 
treatment effected a comparable 57% reduction. Everolimus, 
a 2-hydroxyethyl derivative of sirolimus, had similar inhibi-
tory effects at 10 µM (56% reduction in pre-treated cells 
and 59% in postinfection treatment) (147). Surprisingly, the 
treatment of VeroFM cells with 0.3 µM sirolimus increased 
the SARS-coV-2 infection (143). Presently, a clinical trial 
(NcT04341675) is scheduled to assess sirolimus adminis-
tered as 6 mg on day 1, followed by 2 mg daily for the next 
13 days (56). Metformin could be another repurposed drug 
for cOVId-19 based on its autophagy induction by activation 
of AMP‑activated protein kinase (AMPK) and inhibition of 
mTOR (148,149).
Niclosamide is an oral antihelminthic drug used to treat a 
large array of parasitic infections being included on the WHO 
list of essential medicines (150). In a screening of marketed 
drugs it was identified to protect Vero E6 cells from the 
cytopathic effects of SARS-coV (151). Niclosamide inhibited 
SARS‑CoV replication in Vero E6 cells with a corresponding 
Ec50 value under 0.1 µM, as measured by spike protein 
quantification (152). A yet not peer‑reviewed preprint presents 
the SARS‑CoV‑2 growth inhibition of niclosamide with an 
Ec50 value of 0.17 µM. The authors proposed a mechanism 
of action that implicates the inhibition of SPK2 (143). SPK2 
inhibitors reverse the reduction of BECN1 levels produced by 
SARS-cOV-2 in host cells and enhance autophagy, inhibiting 
the viral replication (142,143). Another possible mechanism 
could be niclosamide's protonophore effect resulting in 
endosomal pH neutralization preventing acid-dependent virus 
replication (153). The maximum plasma concentration after 
500 mg x 3/day oral administration of niclosamide ranged 
from 35.7 to 182 ng/ml, equivalent to 0.1-0.55 µM (154). The 
results showed poor oral bioavailability that could hinder 
immediate clinical utility against cOVId-19. The clinical 
trial NCT04372082 will evaluate niclosamide 500 mg x 4/day 
(day 1) followed by 500 mg x 2/day (days 2‑10) in combina-
tion with diltiazem 60 mg x 3/day (days 1‑10) (56). The use 
of diltiazem is supported by host-targeted antiviral effects 
demonstrated in influenza mouse models (155).
Nitazoxanide, known as 2‑(acetyloxy)‑N‑(5‑nitro‑2‑thi-
azolyl)benzamide, is a structural analog of niclosamide. 
Nitazoxanide is an antiprotozoal agent with proven broad‑spec-
trum antiviral properties. It is a prodrug activated to its desacetyl 
derivative, tizoxanide, by hydrolysis. Both nitazoxanide and 
tizoxanide inhibited MERS-coV replication in LLc-MK2 
cells with mediocre EC50 values of 2.99 µM (0.92 µg/ml) 
and 3.13 µM (0.83 µg/ml), respectively (156). Nitazoxanide 
displayed similar effects on SARS-coV-2 cultured in Vero E6 
cells with an EC50 = 2.12 µM (70). The antiviral mechanism is 
possibly the same as niclosamide, as observed in RAW264.7 
cells treated with tizoxanide. Tizoxanide increased BECN1 
expression, inhibited Akt and mTOR, and promoted the 
formation of autophagy vacuoles (157). A placebo-controlled 
study (NcT04343248) is scheduled to evaluate nitazoxanide 
(300 mg x 2/day) as post-exposure prophylaxis for cOVId-19 
elderly patients, and a related study (NcT04359680) is 
focused on healthcare workers. Other clinical studies will test 
nitazoxanide in combination with hydroxychloroquine or with 
ivermectin (56).
Valinomycin is a toxic natural dodecadepsipeptide that 
also inhibits SPK2 and blocked SARS‑CoV replication in 
Vero E6 cells (Ec50 = 1.63 µM) (152).
Antiviral mechanisms. Umifenovir (also known as arbidol) is a 
broad-spectrum antiviral agent targeting both dNA and RNA, 
and both enveloped and non-enveloped viruses, currently 
used clinically for the prophylaxis and treatment of influenza 
in Russia and China. The antiviral mechanism is not known 
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and is hypothesized to be directly virucidal coupled with 
host-targeting effects (158,159), i.e., potentially polypharmaco-
logical in nature. In a retrospective study on cOVId-19 patients, 
16 people received umifenovir 200 mg x 3/day, and 34 patients 
were treated with the lopinavir (400 mg)/ritonavir (100 mg) 
combination. The umifenovir group had a shorter duration of 
positive SARS-coV-2 RT-PcR tests, suggesting that umife-
novir monotherapy was more effective than lopinavir/ritonavir 
in reducing viral load in cOVId-19 patients (160). Separately, 
a retrospective cohort study analyzed 16 patients who received 
umifenovir and lopinavir/ritonavir versus 17 patients that 
received lopinavir/ritonavir and found an apparent favorable 
clinical response in the former group (161). In a retrospec-
tive study on 45 patients treated with 200 mg umifenovir 
three times a day for 5 days in 8 patients and 7 up to 10 mg 
in the other 37 patients, no severe side effects were observed. 
The median time from admission to the first negative test 
and hospitalization time was longer compared to the control 
group, indicating that umifenovir alone may not accelerate 
SARS-coV-2 clearance (162).
The antiviral effect of umifenovir was only recently inves-
tigated on Vero E6 infected with SARS‑CoV‑2. Umifenovir 
treatment reduced the viral cytopathic effects with an EC50 
value of 4.11 µM, but with a relatively low selectivity (SI=7.73). 
After a single oral dose of 800 mg, the maximal plasma 
concentration in man was ascertained at ~4.1 µM. These data 
suggest that the doses of 200 mg three times a day are too low 
for a physiological relevant antiviral effect (163).
Ivermectin represents a mixture of two semisynthetic aver-
mectins and belongs to the chemical family of 16-membered 
macrocyclic lactones. It is used for over three decades to treat 
various parasitic infections being included on the WHO list of 
essential medicines (164). The antiviral effects of ivermectin 
on various RNA viruses like influenza, Dengue virus, or West 
Nile Virus prompted its evaluation against SARS-coV-2. 
Vero/hSLAM cells were infected with SARS‑CoV‑2 and 
treated with 5 µM ivermectin. After 24 h the viral RNA was 
reduced by 93% in the supernatant and by 99.8% in the cells. 
After 48 h of treatment, the viral RNA decrease was close to 
5,000x (165). The Ec50 value was determined to be ~2 µM and 
the hypothesized mechanism of action implicated blockade of 
viral protein transport in the nucleus by dissociation of the 
host importin α/β1 heterodimer (165,166) - mechanism not in 
line with the exclusively cytosolic life cycle of SARS‑CoV‑2. 
Ivermectin is most frequently used for onchocerciasis, stron-
gyloidiasis, and enterobiasis in doses of 150 to 200 µg/kg, and 
up to 400 µg/kg in patients with lymphatic filariasis (167). A 
clinical study (NcT04343092) is programmed to test iver-
mectin in COVID‑19 patients as a single dose of 200 µg/kg in 
combination with daily doses of hydroxychloroquine (400 mg) 
and azithromycin (500 mg). Two other clinical trials are regis-
tered to test ivermectin, one in combination with chloroquine 
(NcT04351347), and another (NcT04360356) in association 
with nitazoxanide (56).
Emetine is a natural tetrahydroisoquinoline alkaloid from 
ipecac species with potent inhibitory effects on the replication 
of a broad range of dNA and RNA viruses. Emetine displayed 
potent anti‑MERS‑CoV activity in Vero E6 cells, with an 
Ec50 = 0.34 µM (after 72 h) and SI=9.06 (168). The Ec50 value 
against SARS‑CoV‑2 was evaluated as 0.5 µM after 48 h, a 
concentration almost 3‑fold higher than emetine's thera-
peutic plasma concentration (81), hindering its clinical use in 
COVID‑19 patients. Lycorine is a structurally related alkaloid 
found in Amaryllidaceae species, with potent anti‑MERS‑CoV 
effects (Ec50 = 1.63 µM), but with therapeutic doses that 
exceed the toxic ones (168). Homoharringtonine is an alkaloid 
approved as a prodrug derivative, omacetaxine mepesuccinate, 
for chronic myeloid leukemia treatment. It yields potent and 
broad anti-RNA virus effects by reducing the phosphoryla-
tion level of the eukaryotic initiation factor 4E (eIF4E) (169). 
Homoharringtonine reduced SARS-coV-2 viral load in Vero 
E6 cells with an EC50 value of 2.10 µM (81). Zotatifin (eFT226) 
is an inhibitor of eukaryotic initiation factor 4A (eIF4A) 
under evaluation for advanced solid tumor malignancies and 
produced strong antiviral effects in Vero E6 cell models of 
SARS-coV-2 viral infection (170).
A number of antiviral compounds were evaluated against 
SARS‑CoV‑2 with disappointing results. Oseltamivir, a neur-
aminidase inhibitor frequently used for influenza patients 
showed no significant antiviral effects at concentrations under 
100 µM in Vero E6 cell models. The same result was obtained 
for baloxavir acid, the active form of the baloxavir marboxil 
prodrug. In influenza viruses it has been reported to block viral 
RNA synthesis by inhibiting endonuclease activity (81). Other 
influenza neuraminidase inhibitors such as laninamivir, pera-
mivir, and zanamivir had no result on the cytopathic effects of 
SARS-coV-2 activity even at high concentrations (163).
Modulation of the immune defense. The response induced 
by viruses in the human host is a combination of innate and 
acquired immunity that unfolds in a sequence, well known 
in many aspects, but considerably nuanced between distinct 
insults. Thus, foreign matter recognition initiates lympo-
cyte recruitment, to progresses into a resolution phase that 
normally seeks to return to homeostasis (171). The inflam-
matory response to SARS‑CoV‑2 generally begins when 
pathogen-associated molecular patterns (PAMP), such as viral 
RNA, and damage-associated molecular patterns (dAMPs), 
including ATP, dNA, and ASc oligomers, are recognized 
by cell surface and cytosolic PAMP recognition receptors 
(PRRs). The ensuing secretion of pro‑inflammatory cytokines 
and chemokines, such as IL‑6, IFN‑γ, monocyte chemoattrac-
tant protein 1 (McP1), and cXcL10, attracts monocytes and 
T lymphocytes, but, unusually, not neutrophils, to the infected 
site (172). The impact of cytokines is generally increased in 
obesity, which is associated with higher baseline inflammatory 
status, explaining the higher risk of complications for obese 
patients infected with SARS‑CoV‑2 (173).
The cytokine IL‑6 is one of the most important acute 
inflammatory mediators secreted early during an infection, 
along with IL‑1 and TNF‑α (174). Immunosuppressants 
targeting these molecules are needed to reverse the rampant 
immune activation observed in late stage, severe forms of 
cOVId-19 (175). A comprehensive list of immunosuppres-
sive therapies aimed at limiting immune-mediated damage 
produced by SARS-coV-2 infection are presented in Table I.
IL-6 is produced in response to acute inflammation, 
primarily in response to stimulation by TNF-α, lipopolysac-
charides, and IL-1 (179). The cellular sensor for IL-5 is the 
surface-expressed IL-6 receptor (IL-6R; classical signaling 
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pathway) or through soluble IL‑6R (trans‑signaling 
pathway) (180). The first pathway could be anti‑inflam-
matory as IL-6 plays a pivotal role in the polarization of 
immune responses toward Th1, inhibiting the production 
of IFN‑γ by CD4 T cells, and by consequence CD8 T cell 
activation (174). The signaling through soluble IL-6R has 
different consequences. The complex of IL-6 and soluble 
IL-6R can bind to a membrane structure named gp130 on 
cells that do not express IL‑6R, initiating what appear to be 
pro‑infammatory cascades in cells otherwise non‑responsive 
to IL-6 (181).
Several studies report elevations in IL-6 levels in patients 
with COVID‑19 (45,182,183). A retrospective study on 
191 hospitalized cOVId-19 patients from the Wuhan region 
found higher IL-6 levels in the non-survivor group, compared 
to survivors (184). A meta-analysis study reported a 2.9-fold 
higher level of IL‑6 in difficult COVID‑19 cases in contrast to 
non-complicated ones (185). IL-6 has also an essential role in 
the pathophysiology of rheumatoid arthritis being a validated 
target for rheumatoid arthritis therapies (186), driving drug 
repurposing studies for the IL-6 mediated-management of 
cOVId-19.
Tocilizumab is a humanized monoclonal antibody (mAb) 
directed against the IL-6 receptor used as an effective 
therapeutic agent for rheumatoid arthritis patients who do 
not respond to methotrexate (176). A retrospective analysis of 
published studies involving the use of tocilizumab in patients 
with COVID‑19 highlighted the importance of close patient 
monitoring for neutropenia, thrombocytopenia, and elevated 
liver enzymes (187). A pilot prospective open, single-arm 
study evaluated tocilizumab in 63 hospitalized patients 
with severe COVID‑19 to report improved respiratory and 
laboratory parameters (188). Sarilumab is a fully humanised 
monoclonal antibody that specifically binds to both soluble 
and membrane-bound IL-6 receptors (189). Siltuximab and 
clazakizumab are antibodies targeting IL‑6 that are under 
clinical evaluation for severe lung disease associated with 
SARS-coV-2 infection (190).
IL-1 receptor signaling is implicated early in infection, 
preceeding IL‑6 expression. However, it is also responsible 
for acute tissue inflammatory damage. In mice, the cytokine 
storm is associated with elevated levels of IL‑1 (174), and a 
potentiation of TNF-α (191). Using anakinra, the synthetic 
form of natural IL‑1 receptor antagonist, it has been shown in 
mice that IL‑1 signalling blockade could be a potential treat-
ment of influenza infections, arresting airway neutrophilia 
early in the infection cycle, but also during the peak of viral 
replication (192).
TNF-α is a key component of the cytokine response 
and is implicated in cOVId-19 severity, as it is found at 
elevated levels among severe cases (45). There is consider-
able clinical experience globally with several antibodies 
targeting TNF-α in clinic against severe cases of autoimmune 
inflammatory disease, such as rheumatoid arthritis, Crohn's 
disease, ankylosing spondylitis, or psoriasis (193). The idea 
of repurposing anti-TNF-α immunotherapies for the manage-
ment of cOVId-19 is supported by preclinical studies on 
influenza mouse models (193). Adalimumab, a fully human-
ised monoclonal antibody, is under evaluation in cOVId-19 
patients (185).
Activation of the nicotinic receptor α7 on immune cells 
also reduces the levels of IL-6 and TNF-α (171). Based on 
this effect, it has been hypothesized that nicotine, a cholin-
ergic agonist, could have protective effects in cOVId-19 
patients (194). However, it is unlikely that nicotine can be 
used clinically due to its addictive effects and lack of speci-
ficity (171). Rather, a review based on the available literature 
on the impact of smoking on COVID‑19 identified a number 
of studies highlighting a history of smoking as a prognostic 
factor for severe outcomes, while a meta‑analysis study found 
no significant correlation between smoking and the severity of 
cOVId-19 disease (195).
The interferon family, whose expression is induced directly 
and indirectly following viral PAMP recognition, is critical in 
directing innate and adaptive immunity direction. Thus, the 
interferon cascade induces multiple host antiviral factors or 
immunomodulators. Activation of either of the two members of 
the IFN-α receptor (IFNAR) family initiates cytosolic signal-
ling cascades culminating in the transcriptional activation of 
numerous IFN-stimulated genes (ISGs). The protein products 
of these transcripts exhibit antiviral principally through inhi-
bition of viral replication. Furthermore, type I IFNs enhance 
natural killer cell activity and antiviral T cell responses, which 
are central to antiviral defence (196).
A comprehensive evaluation of the therapies tested in the 
SARS‑CoV outbreak found two studies reporting IFN‑α ther-
apies in combination with steroids and/or ribavirin, without a 
significant difference in the clinical outcome when compared 
to other therapies used (140). A preprint report suggests a 
higher susceptibility of SARS-coV-2 to type I IFN treatment 
compared to SARS‑CoV (197). These results were reaf-
firmed on Vero cells treated with IFN‑α or IFN-β, returning 
Ec50 values for SARS-coV-2 at 1.35 IU/ml for IFN-α, and 
0.76 IU/ml for IFN-β. In contrast, SARS-coV Ec50 values 
were reported to range between 95 to 105 IU/ml depending on 
the viral strains used (198).
Several immunosuppressants are also being examined 
as potential solutions for severe COVID‑19, with the highest 
interest being in drugs such as methotrexate, JAK inhibitors 
(ruxolitinib, baricitinib, tofacitinib, imatinib), colchicine, 
thalidomide, and lenalidomide. Methotrexate-loaded 
nanoparticles administered intravenously at 20 mg, once 
per week (total of 4 doses), is under evaluation in one trial 
(NCT04352465) (56). Imatinib, an Abl kinase inhibitor and 
to a lesser extent, a JAK/STAT inhibitor, is used as an experi-
mental drug in elderly cOVId-19 patients in out-of-hospital 
settings at doses of 400 mg/day, 7 days (NcT04346147, 
NcT04357613, NcT04356495) (56). colchicine presents 
long-established anti-inflammatory properties and neutro-
phil inhibitory effects and is currently under evaluation 
in cOVId-19 patients (NcT04322682, NcT04322565, 
NcT04328480, NcT04326790, NcT04350320) (184,199). 
Thalidomide plus low doses of glucocorticoids, umifenovir, 
and IFN-α aerosols have been used in NcT04273581 and 
NcT04273529. Lenalidomide, a structural derivative of 
thalidomide, is currently under evaluation as 4 mg/day on 
days 1, 3 and 5, in less severe cases of cOVId-19 associated 
with low‑molecular weight heparin (NCT04361643) (56). 
Eculizumab is a recombinant humanized monoclonal antibody 
that targets complement component 5 and is under clinical 
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study in 900-1200 mg doses administered intravenously 
(NcT04355494) (56).
Dietary supplements. Ascorbic acid or vitamin c is an estab-
lished antioxidant and reactive oxygen species scavenger widely 
considered to alleviate or prevent infections (200). Vitamin c 
was proposed as a supportive treatment for COVID‑19 and 
several clinical trials are registered to assess its effects. The 
clinical study NcT04323514 uses intravenous administration 
of 10 g of vitamin C, while study NCT04342728 uses 8 g of 
ascorbic acid divided into 2-3 doses/day alone or combined 
with 50 mg of zinc gluconate, and the NCT04344184 study 
uses 100 mg/kg vitamin C intravenously administered every 
8 h for up to 72 h (56). An article details a chinese expert report 
on clinical improvement of 50 moderate to severe cOVId-19 
patients treated intravenously with 10‑20 g/day (201). 
Vitamin D influences the immune response by modulating 
several immune pathways and its deficiency was correlated 
with increased risks of respiratory infections (202). The 
clinical study NCT04334005 will test administration of a 
single dose of 25,000 IU of vitamin d as supplement in addi-
tion to standard therapies, while in NCT04334005 vitamin D 
will be given orally as 50,000 IU once weekly for 2 weeks 
in combination with 81 mg of acetylsalycilic acid (56). Zinc 
has anti-inflammatory effects moderating T cell functions 
that could limit excess cytokine production in COVID‑19 
patients (203). Selenium supplementation was shown to 
increase immunity and could be used in SARS-coV-2 infec-
tions (204). The clinical study NcT04323228 is scheduled 
to test an oral supplement enriched in eicosapentaenoic acid, 
gamma-linolenic acid containing 18 µg selenium and 5.7 mg 
zinc (56).
Oligonucleotide and gene therapy‑based approaches. With 
the precise mechanism of SARS-coV-2 migration from 
respiratory epithelia onto distal AcE2-expressing organs 
remaining unclear, direct intervention at the RNA genome 
level of SARS-coV-2 is also attracting research attention. 
However, efforts in this space, compared to the advanced 
nature of vaccine and small molecule intereventions, can only 
be characterized as speculative and preliminary.
The most clinically advanced drug classes in this space 
are short interfering RNA (siRNA) and ribonuclease H 
(RNaseH)-active oligonucleotide antisense therapeutics, 
modalities that have enjoyed serial regulatory approval 
successes and become commercially viable since 2016. Thus, 
first pass metabolism affords adequate passive liver uptake 
after systemic administration to tackle hereditary hepatic 
diseases [e.g., mipomersen (205)]. Similarly, intrathecal 
administration of antisense has proven an effective interven-
tion against spinal muscular atrophy [nusinersen (206)] and 
ushered true n-of-1 medicine [milasen (207)]. Yet all clinical 
candidates evaluated between 2000‑2011 for lung diseases 
of inflammatory or viral nature achieved ambiguous and 
inadequate outcomes, despite the apparent facility of topical 
dosing to the airways (208). This has been largely attributed 
to misconceptions around systemic bioavailability and topical 
cytosolic delivery potential, as rodent studies of oligonucle-
otide bioavailability following respiratory dosing (32) reflect 
allometrically scaled human pharmacokinetics even onto 
demonstrating effective hepatic and kidney targeting (32,209). 
does this preclude topical intervention to prevent AcE2 
receptor docking of SARS‑CoV‑2? Unfortunately, even the 
single clinical stage antisense candidate AZd1419 targeting 
the cell surface TLR9 to improve time-to-loss of eosinophilic, 
moderate-to-severe asthma control, also reportedly failed to 
meet primary endpoints in the phase 2a INcONTRO trial 
(NcT02898662) (56). Although clarity over respiratory TLR9 
coverage by the adopted dosing regime remains undetermined, 
direct comparisons are ill-advised, thus focusing future inter-
vention efforts in four areas.
At first instance, aptamer‑mediated inhibition of ACE2 
binding and TMPRSS2 activity, either solely or as a combi-
nation therapy, presents a rational means of intervention 
to prevent viral adhesion and cellular entry, similar to that 
proposed by small molecule inhibitors. Although cost of 
goods, chemistry, manufacturing and control requirements 
are significantly higher for this chemotherapeutic class 
vs small molecule drugs, rapid hit generation by modern 
aptamer development methods (210,211) and established 
orthogonal aptamer optimization strategies can deliver 
clinical candidates compatible with scalable manufacturing 
pertinent to pandemic outbreaks, in timelines comparable 
or better than antibody biotherapeutics. Thus, in the event 
of complete failure across the vast number of repurposed 
medication trials described in this review, a second wave 
of aptamer-based treatments could be ready for subsequent 
clinical testing. Significantly, systemic access achieved 
through the lung (32) may afford distal tissue protection from 
SARS-coV-2 infection.
The following approaches would involve the generation of 
antisense, siRNA chemo- and biotherapeutics (dNA directed 
RNA interference mediators in the form of short hairpin 
RNA (shRNA) precursors), or cRISPR-cAS13 systems (212) 
that would seek to directly cleave the RNA genome of 
SARS‑CoV‑2. Cytosolic delivery challenges notwithstanding, 
the paucity of reports indicating multi-log suppression of 
viral replication by these chemotherapeutic classes irrespec-
tive of target RNA virus, and the diverse evidence of rapid 
viral evolutionary escape, combination therapy is likely to 
be necessary (213) to afford either protection, or treatment 
against SARS-coV-2 by any such agents. In this respect, 
RNA-cleaving cRISPR-cAS13 systems suffer from macromo-
lecular ribonucloprotein complex requirements that compound 
drug delivery challenges vs the relatively smaller molecular 
weight of oligonucleotides, that rely on host proteins to exert 
their mechanism of action.
Poignantly, the only modality proven to achieve cytosolic 
delivery in the lung are adeno-associated virus 6 biotherapeu-
tics (214,215) for the minigene treatment of cystic fibrosis (216). 
Although this drug class has yet to be attempted against viral 
respiratory diseases, the safety of AAV-mediated triple anti-
viral shRNA expression has been demonstrated in man even 
onto phase IIb against HcV (NcT01899092). consequently, 
a brief anti-SARS-coV-2 shRNA discovery and optimization 
campaign coupled to promoter optimization experiments (217) 
in physiologically relevant organoid models could yield a 
high confidence‑in‑safety and confidence‑in‑rationale candi-
date drug with the potential to suppress viral escape (218) if 
adequately tuned to express shRNAs in vivo without inter-
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rupting microRNA homeostasis. Significantly, the approach 
benefits from a ‘fire and forget’, single, inhaled administration 
that would mediate transgene expression within 3 days of 
dosing and for up to 6 months (217), or potentially longer. It is, 
therefore, proposed that such an intervention may compensate 
for broad-spectrum, short-term protection from SARS-coV-2 
infection in high risk populations in the event of failure to 
deliver protective vaccines, or vaccination ineligibility due 
underlying immunosuppression.
5. Discussion
Assembling this review was an exciting and laborious daunting 
task, considering the astonishing volume of research published 
and the urgency of finding effective, yet safe, therapeutical 
solutions for cOVId-19. The high pressure on the research 
community leads both to very good studies and publications, 
but also hasty and poorly designed studies, biased conclusions, 
or unproven hypotheses, all mixed together. The research 
directions were heavily influenced by the evolution of the 
COVID‑19 epidemic. At the early stages of the outbreak in 
china, patients received oseltamivir based on the erroneous 
diagnosis of influenza. Even if neuraminidase, the target of 
oseltamivir, was invalidated for COVID‑19 treatments, several 
ongoing clinical trials still include oseltamivir as a comparison 
group (51).
Repurposing was also a rapid response solution based on 
the experience with SARS‑CoV, MERS‑CoV, or with other 
viruses. Many of the repurposed drugs undergoing clinical 
trials were not tested in cell models against SARS‑CoV‑2, 
raising questions about their real efficacy. Even so, the cell 
models can be misleading because most compounds have 
not been tested on human cells and because only Ec50 values 
are reported without clear information on the dose‑response 
curve. Several conditions such as different multiplicities of 
infection or time of exposure can dramatically influence the 
Ec50 values. There are several other concerns that are worth 
mentioning: the potential of a drug to reach the target tissue 
and how it would perform under complex, disease‑altered 
conditions (Fig. 4).
Future research should focus on how the virus evades the 
immune response and try to better understand its interaction 
with the T and B cell responses, both in the humans and 
experimentally infected animals. The second goal should be 
to reveal and assess details of viral replication strategies and 
pathways, determining the relationship between sites of viral 
RNA replication and virus assembly, as well as the extent to 
which virus‑host interactions are SARS‑CoV‑2 specific and 
organ‑specific, using genomics and proteomics, as well as 
new reagents. A third future goal should be to translate new 
information about the structure and function of SARS-coV-2 
proteins into specific anti‑virus therapies, particularly with 
respect to the SARS‑CoV‑2 proteins of unknown function. The 
next goal will be the understanding of viral pathogenesis, to 
design and develop effective live or attenuated safe vaccines. 
It is anticipated that, like other RNA viruses, subgenomic 
SARS‑CoV‑2 replicon systems adapted to lung, kidney, and 
even neuronal cell types will catalyse the understanding of 
SARS-coV-2 biology.
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